Immunotherapy has historically shown minimal to no efficacy in EGFR-mutant NSCLC, with multiple retrospective and prospective studies demonstrating low response rates to checkpoint inhibitors as monotherapy or in combination with chemotherapy (56–59). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.